MacroGenics (MGNX) News Today $3.35 +0.01 (+0.30%) (As of 10:03 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period MacroGenics, Inc. (NASDAQ:MGNX) Receives $7.63 Consensus Price Target from BrokeragesDecember 18 at 3:39 AM | americanbankingnews.comMacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Recommendation of "Hold" by BrokeragesShares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have received a consensus recommendation of "Hold" from the eleven research firms that are presently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold rating, two have assigned a buyDecember 15 at 2:50 AM | marketbeat.comMGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating Macrogenics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmDecember 10, 2024 | globenewswire.comJacobs Levy Equity Management Inc. Buys 147,438 Shares of MacroGenics, Inc. (NASDAQ:MGNX)Jacobs Levy Equity Management Inc. grew its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 35.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 566,328 shares of the biopharmaceutical company's stock after acquiring aDecember 8, 2024 | marketbeat.comMacroGenics to Participate in Upcoming Investor ConferenceDecember 2, 2024 | globenewswire.comConnor Clark & Lunn Investment Management Ltd. Boosts Holdings in MacroGenics, Inc. (NASDAQ:MGNX)Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 39.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 661,914 shares of the biopharmaceuticNovember 26, 2024 | marketbeat.comMacroGenics Announces Leadership Transition in Financial RolesNovember 21, 2024 | markets.businessinsider.comMacroGenics, Inc. (MGNX) Shareholder Alert: Grabar Law Office Investigates Claims on Your BehalfNovember 21, 2024 | markets.businessinsider.comMacroGenics, Inc. (NASDAQ:MGNX) Receives Average Rating of "Hold" from AnalystsMacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) has earned an average rating of "Hold" from the eleven analysts that are currently covering the company, MarketBeat reports. Eight equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assignedNovember 20, 2024 | marketbeat.comNotice to MacroGenics, Inc. (MGNX) Shareholders: Grabar Law Office Investigates Claims on Your BehalfNovember 14, 2024 | markets.businessinsider.comFY2024 Earnings Estimate for MacroGenics Issued By B. RileyMacroGenics, Inc. (NASDAQ:MGNX - Free Report) - Analysts at B. Riley issued their FY2024 earnings estimates for shares of MacroGenics in a research report issued on Wednesday, November 6th. B. Riley analyst M. Mamtani expects that the biopharmaceutical company will post earnings of $0.00 per sharNovember 11, 2024 | marketbeat.comMacroGenics (NASDAQ:MGNX) Upgraded to Buy at StockNews.comStockNews.com upgraded MacroGenics from a "sell" rating to a "buy" rating in a research report on Sunday.November 10, 2024 | marketbeat.comFY2024 EPS Estimates for MacroGenics Boosted by AnalystMacroGenics, Inc. (NASDAQ:MGNX - Free Report) - Research analysts at HC Wainwright raised their FY2024 earnings estimates for shares of MacroGenics in a research note issued on Wednesday, November 6th. HC Wainwright analyst R. Burns now forecasts that the biopharmaceutical company will post earniNovember 8, 2024 | marketbeat.comLeerink Partnrs Forecasts Increased Earnings for MacroGenicsMacroGenics, Inc. (NASDAQ:MGNX - Free Report) - Leerink Partnrs upped their FY2024 EPS estimates for MacroGenics in a report issued on Wednesday, November 6th. Leerink Partnrs analyst J. Chang now expects that the biopharmaceutical company will post earnings of ($1.24) per share for the year, upNovember 8, 2024 | marketbeat.comAttention Macrogenics, Inc. (MGNX) Shareholders: Grabar Law Office Investigates Potential Claims on Your BehalfNovember 8, 2024 | markets.businessinsider.comMacroGenics downgraded to market perform by JMP, price target removedNovember 7, 2024 | msn.comMacroGenics (MGNX) was downgraded to a Hold Rating at JMP SecuritiesNovember 7, 2024 | markets.businessinsider.comMacroGenics (NASDAQ:MGNX) Downgraded to Market Perform Rating by JMP SecuritiesJMP Securities cut MacroGenics from an "outperform" rating to a "market perform" rating in a report on Thursday.November 7, 2024 | marketbeat.comMacroGenics’ Transition Phase: Balancing Potential and Uncertainty Amid Leadership and Pipeline DevelopmentsNovember 7, 2024 | markets.businessinsider.comMacrogenics Inc (MGNX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic DevelopmentsNovember 7, 2024 | finance.yahoo.comMacroGenics’ Strategic Moves and Promising Pipeline Justify Buy RatingNovember 7, 2024 | markets.businessinsider.comMacroGenics (MGNX) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | msn.comMacroGenics to Participate in Upcoming Investor ConferencesNovember 6, 2024 | globenewswire.comMacroGenics' (MGNX) "Neutral" Rating Reiterated at HC WainwrightHC Wainwright reissued a "neutral" rating and set a $4.00 price objective on shares of MacroGenics in a research report on Wednesday.November 6, 2024 | marketbeat.comMacroGenics, Inc. (MGNX) Q2 2024 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comMacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial ResultsNovember 5, 2024 | globenewswire.comMacrogenics Earnings PreviewNovember 4, 2024 | benzinga.comEarnings To Watch: Macrogenics Inc (MGNX) Reports Q3 2024 ResultNovember 4, 2024 | finance.yahoo.comMacroGenics (NASDAQ:MGNX) Stock Rating Lowered by StockNews.comStockNews.com lowered MacroGenics from a "hold" rating to a "sell" rating in a report on Saturday.November 2, 2024 | marketbeat.comMacroGenics announces CEO Koenig to step downOctober 31, 2024 | markets.businessinsider.comMacroGenics, Inc.: MacroGenics Announces Leadership TransitionOctober 30, 2024 | finanznachrichten.deMacroGenics Co-Founder Koenig Stepping Down as President, CEOOctober 30, 2024 | marketwatch.comMacroGenics Announces CEO Transition Amidst Strong GrowthOctober 30, 2024 | msn.comMacroGenics (MGNX) Scheduled to Post Earnings on TuesdayMacroGenics (NASDAQ:MGNX) will be releasing earnings after the market closes on Tuesday, November 5, Zacks reports.October 30, 2024 | marketbeat.comMacroGenics Announces Leadership TransitionOctober 30, 2024 | globenewswire.comMacroGenics Announces Date of Third Quarter 2024 Financial Results Conference CallOctober 29, 2024 | globenewswire.comMacroGenics, Inc. (NASDAQ:MGNX) Receives Average Rating of "Hold" from BrokeragesShares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have been assigned a consensus recommendation of "Hold" from the eleven analysts that are presently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a hold recommendation, three have assigned a buy reOctober 26, 2024 | marketbeat.comMacroGenics (NASDAQ:MGNX) Stock Rating Upgraded by StockNews.comStockNews.com raised MacroGenics from a "sell" rating to a "hold" rating in a report on Friday.October 25, 2024 | marketbeat.comMacroGenics (MGNX) Receives a Rating Update from a Top AnalystOctober 24, 2024 | markets.businessinsider.comMacroGenics to Sell Margenza Cancer Drug for $40 MillionOctober 23, 2024 | marketwatch.comMacroGenics in $40M deal with TerSera Therapeutics for sale of MargenzaOctober 23, 2024 | markets.businessinsider.comMacroGenics (MGNX) Receives a Buy from JMP SecuritiesOctober 23, 2024 | markets.businessinsider.comMacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®October 22, 2024 | businesswire.comDimensional Fund Advisors LP Lowers Stake in MacroGenics, Inc. (NASDAQ:MGNX)Dimensional Fund Advisors LP trimmed its position in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 14.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 898,497 shares of the biopharmaceutical comOctober 10, 2024 | marketbeat.comMillennium Management LLC Grows Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX)Millennium Management LLC boosted its position in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 3,473.7% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 3,312,672 shares of the biopharmaceutical company's stock after acquiring an additional 3,219,977 shares dOctober 7, 2024 | marketbeat.comMarshall Wace LLP Grows Stake in MacroGenics, Inc. (NASDAQ:MGNX)Marshall Wace LLP grew its position in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 1,689.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 658,007 shares of the biopharmaceutical company's stock after purchasingOctober 4, 2024 | marketbeat.comRenaissance Technologies LLC Sells 231,000 Shares of MacroGenics, Inc. (NASDAQ:MGNX)Renaissance Technologies LLC lowered its stake in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 32.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 484,027 shares of the biopharmaceutical company's stock aOctober 3, 2024 | marketbeat.comFrazier Life Sciences Management L.P. Has $12.80 Million Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX)Frazier Life Sciences Management L.P. lifted its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 21.8% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 3,010,727 shares of the biopharmaceutical company's stock after buying anSeptember 29, 2024 | marketbeat.comHere's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash WiselySeptember 26, 2024 | finance.yahoo.comArmistice Capital LLC Grows Stock Position in MacroGenics, Inc. (NASDAQ:MGNX)Armistice Capital LLC raised its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 150.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,000,000 shares of the biopharmaceutical companySeptember 26, 2024 | marketbeat.com Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Forced out of retirement by these trades (Ad)You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed Make sure to check out Gamma Pockets HERE while it’s still widely available MGNX Media Mentions By Week MGNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MGNX News Sentiment▼1.340.65▲Average Medical News Sentiment MGNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MGNX Articles This Week▼28▲MGNX Articles Average Week Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Anavex Life Sciences News Immunome News Kura Oncology News Keros Therapeutics News Tyra Biosciences News Erasca News Cronos Group News Evolus News Dianthus Therapeutics News Rapport Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MGNX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
